A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality

This study has suspended participant recruitment.
Sponsor:
Collaborator:
Ben-Gurion University of the Negev
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00569413
First received: December 6, 2007
Last updated: June 9, 2010
Last verified: June 2010
  Purpose

The current study combines a molecular genetic perspective, self report and brain imaging to the study of human sexuality in control subjects and individuals from a sexual disorder clinic. The investigators hypothesize that the variability in components of the brain dopaminergic system expressed in the mesolimbic reward system can explain variability in human sexuality, especially in desire and pleasure associated with sex.


Condition
Hypoactive Sexual Desire Disorder
Erectile Dysfunction

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Brain Imaging data of DRD2 receptor occupancy during watching a sex videotape and neutral videotape [ Time Frame: 2 Brain imaging sessions a week apart ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Questionnaire ratings of human sexuality, pleasure, and anticipatory reward [ Time Frame: Taken during brain scans ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: April 2011
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
2
20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.

Detailed Description:

We intend to combine molecular genetics of the dopamine receptors (D2, D3 D4 and D5) and brain imaging using 11 C Raclopride in Positron Emission Tomography (PET). 11 C Raclopride is a ligand which binds to the dopamine receptor D2 and can measure dopamine release during pleasure or anticipatory reward associated with sex. The current proposal will measure changes in DRD2 receptor occupancy using 11 C Raclopride following explicit visual sexual desire cues in healthy control subjects and individuals who suffer from sexual dysfunction. This is in order to determine how individual genotypes modulate dopamine release in vivo in the human brain.

  Eligibility

Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

A group of healthy volunteers from the general public. A group of patients who suffer from sexual disorder from a primary care clinic.

Criteria

Inclusion Criteria:

  • Healthy volunteers and patients
  • Age 21-65
  • Male or female

Exclusion Criteria:

  • Psychiatric diagnosis/psychosis
  • Neurological damage associated with loss of consciousness
  • Infectious disease HIV
  • Herpes
  • Syphilis
  • Hyperactivity treated with ritalin
  • Pregnant women
  • Under age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00569413

Sponsors and Collaborators
Hadassah Medical Organization
Ben-Gurion University of the Negev
Investigators
Principal Investigator: Aviv M Weinstein, Ph.D Hadasah Medical Organization, Jerusalem Israel
  More Information

No publications provided

Responsible Party: Prof. Roland Chisin, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00569413     History of Changes
Other Study ID Numbers: 281207HMO-CTIL, First 978[1].07
Study First Received: December 6, 2007
Last Updated: June 9, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
Sex
brain imaging
dopamine
sexual disorder

Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological
Hypokinesia
Erectile Dysfunction
Sexual and Gender Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Sexual Dysfunction, Physiological
Genital Diseases, Male

ClinicalTrials.gov processed this record on August 28, 2014